Arkayli Biopharma Inc. Receives Study May Proceed Response to IND from FDA and SBIR Grant from NIH to Advance Clinical Development of ARK001 for a Rare Pediatric Disease

Study May Proceed (SMP) letter is based on IND filing to conduct a Phase 1b Trial of ARK001 in Infants with Infantile Hemangioma (IH) NIH SBIR grant of $2.98 Million acknowledges the high unmet need for a non-systemic treatment for IH Appointment of new CEO, Katie MacFarlane, PharmD, to...